Account
Inquiry
Retatrutide is a novel triple agonist peptide that simultaneously targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). As one of the premium rui products for research purposes, it demonstrates significant potential in metabolic disorder studies.
This synthetic peptide exhibits potent glucose-lowering effects through its unique mechanism of action. Retatrutide stimulates insulin secretion while suppressing glucagon production in a glucose-dependent manner, making it particularly valuable for type 2 diabetes research. The rui products line includes this compound in various concentrations to meet different research requirements.
In preclinical studies, Retatrutide has demonstrated multiple beneficial effects including delayed gastric emptying, reduced fasting glucose levels, decreased food intake, and significant weight loss. These properties make it an important tool for obesity and metabolic syndrome research.
The rui products formulation of Retatrutide is provided as a white lyophilized powder with excellent water solubility (5mg/ml). It maintains stability when stored at -20°C, ensuring reliable performance in research applications. Our facility produces this compound under strict quality controls to guarantee consistent purity and performance.
As with all rui products in this category, Retatrutide is intended for research use only and not for human consumption. Researchers should handle this material with appropriate precautions in laboratory settings.
